Alpha 2.0
Login Register
» Articles » PMID: 30670142

Detection of Influenza A(H3N2) Viruses Exhibiting Reduced Susceptibility to the Novel Cap-dependent Endonuclease Inhibitor Baloxavir in Japan, December 2018

Overview
Journal Euro Surveill
Specialty Infectious Diseases
Date 2019 Jan 24
PMID 30670142
Citations 46
Authors
Emi Takashita
Chiharu Kawakami
Hiroko Morita
Rie Ogawa
Seiichiro Fujisaki
Masayuki Shirakura
Hideka Miura
Kazuya Nakamura
Noriko Kishida
Tomoko Kuwahara
Keiko Mitamura
Takashi Abe
Masataka Ichikawa
Masahiko Yamazaki
Shinji Watanabe
Takato Odagiri
Affiliations
Soon will be listed here.
Abstract

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.

Citing Articles

Broad-spectrum activity against mosquito-borne flaviviruses achieved by a targeted protein degradation mechanism.

Liu H, Li Z, Reindl T, He Z, Qiu X, Golden R Nat Commun. 2024; 15(1):5179.

PMID: 38898037 PMC: 11187112. DOI: 10.1038/s41467-024-49161-9.

The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.

Taniguchi K, Noshi T, Omoto S, Sato A, Shishido T, Matsuno K Arch Virol. 2024; 169(2):29.

PMID: 38216710 PMC: 10786730. DOI: 10.1007/s00705-023-05958-5.

Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir.

Nezu K, Hayashida S, Nagano N, Udagawa S, Morioka I Medicina (Kaunas). 2023; 59(9).

PMID: 37763660 PMC: 10533152. DOI: 10.3390/medicina59091543.

Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets.

Haas K, McGregor M, Bouhaddou M, Polacco B, Kim E, Nguyen T Nat Commun. 2023; 14(1):6030.

PMID: 37758692 PMC: 10533562. DOI: 10.1038/s41467-023-41442-z.

Arbidol: The current demand, strategies, and antiviral mechanisms.

Kang Y, Shi Y, Xu S Immun Inflamm Dis. 2023; 11(8):e984.

PMID: 37647451 PMC: 10461429. DOI: 10.1002/iid3.984.

References
1.
Aoki F, Boivin G, Roberts N . Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007; 12(4 Pt B):603-16. View
2.
. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012; 87(39):369-74. View
3.
Koszalka P, Tilmanis D, Hurt A . Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017; 11(3):240-246. PMC: 5410715. DOI: 10.1111/irv.12446. View
4.
Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M . Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018; 8(1):9633. PMC: 6018108. DOI: 10.1038/s41598-018-27890-4. View
5.
Hayden F, Sugaya N, Hirotsu N, Lee N, de Jong M, Hurt A . Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018; 379(10):913-923. DOI: 10.1056/NEJMoa1716197. View